BioPharmSignal logoBioPharmSignal

Biotech News

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

Catalyst Biosciences (CBIO)Catalyst BiosciencesCommercial

SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to

Open original release

Related news

CBIOCatalyst Biosciences2026-03-17 11:00 EST

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

CBIOCatalyst Biosciences2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

View all latest news

Catalyst Biosciences

Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.

Recent company news

CBIOCatalyst Biosciences2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

CBIOCatalyst Biosciences2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

CBIOCatalyst Biosciences2026-03-17 11:00 EST

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

CBIOCatalyst Biosciences2026-03-12 10:00 EST

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CBIOCatalyst Biosciences2026-03-02 13:00 EST

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

Stock data

Close
16.93 USD
Market cap
468.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States